Le Lézard
Classified in: Health, Science and technology
Subjects: Photo/Multimedia, Product/Service

Edenbridge Pharmaceuticals Announces U.S. FDA Approval of DARTISLA ODT (Glycopyrrolate) Orally Disintegrating Tablets


Edenbridge Pharmaceuticals, LLC ("Edenbridge") today announced that it has received approval from the U.S. Food and Drug Administration on its 505(b)(2) New Drug Application (NDA) for DARTISLA ODT (glycopyrrolate) orally disintegrating tablets. DARTISLA ODT is available in a 1.7 mg orally disintegrating tablet and is indicated for adults to reduce symptoms of a peptic ulcer as an adjunct to treatment of peptic ulcer. Edenbridge will launch this product to the market in early 2022 as its first branded specialty prescription product.

"We are thrilled to receive approval for DARTISLA ODT, which will provide physicians and patients with a novel treatment option," remarked Daniel G. Worley Jr., Edenbridge's Vice President of Business Development and Associate General Counsel. "This marks a major milestone for Edenbridge as our first 505(b)(2) NDA to receive approval from the FDA. We look forward to this new chapter for our company as we continue our strategic expansion into branded specialty prescription products."

DARTISLA ODT is manufactured by Catalent (NYSE: CTLT) using their proprietary Zydis® orally disintegrating tablet delivery technology to create a freeze-dried tablet that disperses almost instantly in the mouth without water.

Patients receiving the 2 mg dosage strength of another oral tablet dosage form of glycopyrrolate may be switched to the 1.7 mg dosage strength of DARTISLA ODT. DARTISLA ODT is not recommended for patients initiating treatment or receiving maintenance treatment with a lower dosage strength of another oral glycopyrrolate product (e.g., tablet strength of 1 mg). Patients who are at risk for anticholinergic toxicity due to various underlying medical conditions or who have hypersensitivity to glycopyrrolate or the inactive ingredients should not take DARTISLA ODT. Adverse reactions include blurred vision, drowsiness, decreased sweating, flushing, vomiting, constipation, dry mouth, tachycardia, and urinary retention. Please visit www.Dartisla.com and consult the full prescribing information for additional important information.

About Edenbridge

Edenbridge is a specialty pharmaceutical company focused on identifying, developing, and marketing prescription pharmaceutical products. Edenbridge's goal is to create a broad portfolio of limited source branded and generic pharmaceutical products that will provide high-quality, affordable, and accessible alternatives in the healthcare market. Edenbridge's approach is to work with best-in-class and like-minded industry partners to deliver its products to physicians and patients everywhere. Founded in 2008, Edenbridge launched its first product in February 2010 and has sold its commercial products through every major channel of the U.S. prescription pharmaceutical supply chain. In addition, Edenbridge has a robust product development pipeline that includes 505(b)(2) NDAs, ANDAs, and foreign filings. For more information, visit www.edenbridgepharma.com or contact the Company directly at [email protected].


These press releases may also interest you

at 04:19
In the news release, SEMIFIVE Starts Mass Production of its 14nm AI Inference SoC Platform based Product, issued 27-Mar-2024 by SEMIFIVE over PR Newswire, we are advised by the company that the sixth paragraph, first sentence, should read "'AI...

at 04:10
Storytel's Annual Report and Sustainability Report 2023 is now published and available as a downloadable PDF document on our website.  FNCA Sweden AB is the Company's Certified Adviser. For more information, please contact:Mattias Frithiof, Head of...

at 04:00
Yukon Group, Europe's leading thermal imaging and night vision company, has launched the world's first upgradable thermal monocular for civilian use. The Pulsar Telos LRF XP50 is set to become an indispensable tool for hunters, explorers and rescuers...

at 04:00
Growing Bolder, a leading lifestyle content producer, and OTT Advisors (OTTA), a leading advisory service for digital strategy, are partnering to launch the world's first active-lifestyle streaming platform for the world's fastest-growing and most...

at 03:40
KLab Inc. announced that its hit 3D action game Bleach: Brave Souls will be holding the Thousand-Year Blood War Zenith Summons: Reinforcements from Sunday, March 31. See the original press release (https://www.klab.com/en/press/) for more...

at 03:30
Electric vehicles (EVs) are a primary method to reach a net zero transportation sector, but in addition to CO2 emissions, overall sustainability is becoming an increased focus point. However, sustainability is a very complex topic that does not tend...



News published on and distributed by: